MBX Earnings — MBX Biosciences, Inc. Common Stock Post-ER Performance | BigEarnings
MBX — MBX Biosciences, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$31.47
Market Cap$1.5B
P/E—
52W Range$9.43 – $45.85
Next Earnings2026-11-05
About MBX Biosciences, Inc. Common Stock
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
